Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

Cancer Immunology Research

Volumn 2, Issue 7, 2014, Pages 632-642

  Hodi, F Stephen ^a   Lawrence, Donald ^b   Lezcano, Cecilia ^g   Wu, Xinqi ^a   Zhou, Jun ^a   Sasada, Tetsuro ^a   Zeng, Wanyong ^a   Giobbie Hurder, Anita ^a   Atkins, Michael B ^h   Ibrahim, Nageatte ^a   Friedlander, Philip ⁱ   Flaherty, Keith T ^b   Murphy, George F ^c   Rodig, Scott ^c   Velazquez, Elsa F ^d,f   Mihm, Martin C ^c   Russell, Sara ^c   Di Piro, Pamela J ^a   Yap, Jeffrey T ^a   Ramaiya, Nikhil ^a   Van Den Abbeele, Annick D ^a   Gargano, Maria ^a   McDermott, David ^e   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d TUFTS UNIVERSITY   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f MIRACA LIFE SCIENCES   (United States)

^g UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER ANTIBODY; IPILIMUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; BIOSYNTHESIS; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; HUMAN; IMMUNOLOGY; MALE; MELANOMA; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHASE 1 CLINICAL TRIAL; SECONDARY; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; VASCULARIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME;

EID: 84964313298     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0053     Document Type: Article

References (36)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
2. Robert C, Thomas L, Bondarenko I, O'Day S, Weber JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
3. Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, et al. Pretreatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014; 2: 127-32.
4. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001; 23: 263-72.
5. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998; 160: 1224-32.
6. Kandalaft LE, Motz GT, Busch J, Coukos G. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. Curr Top Microbiol Immunol 2011; 344: 129-48.
7. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003; 100: 4712-7.
8. Braghiroli MI, Sabbaga J, Hoff PM. Bevacizumab: overview of the literature. Expert Rev Anticancer Ther 2012; 12: 567-80.
9. Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Anti-angiogenic therapy for cancer: an update. Pharmacotherapy 2012; 32: 1095-111.
10. Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors-a meta-analysis and systematic review. PLoS ONE 2013; 8: e51780.
11. Miyake TM, Sood AK, Coleman RL. Contemporary use of bevacizumab in ovarian cancer. Expert Opin Biol Ther 2013; 13: 283-94.
12. Yeung Y, Tebbutt NC. Bevacizumab in colorectal cancer: current and future directions. Expert Rev Anticancer Ther 2012; 12: 1263-73.
13. Khasraw M, Simeonovic M, Grommes C. Bevacizumab for the treatment of high-grade glioma. Expert Opin Biol Ther 2012; 12: 1101-11.
14. Small AC, Oh WK. Bevacizumab treatment of prostate cancer. Expert Opin Biol Ther 2012; 12: 1241-9.
15. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman Vj, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-34.
16. Johnson-Leger C, Aurrand-Lions M, Imhof BA. The parting of the endothelium: miracle, or simply a junctional affair? J Cell Sci 2000; 113 (Pt 6): 921-33.
17. Borgstrom P, Hughes GK, Hansell P, Wolitsky BA, Sriramarao P. Leukocyte adhesion in angiogenic blood vessels. J Clin Invest 1997; 99: 2246-53.
18. Marelli-Berg FM, Clement M, Mauro C, Caligiuri G. An immunologist's guide to CD31 function in T-cells. J Cell Sci 2013; 126: 2343-52.
19. Ma L, Cheung KC, Kishore M, Nourshargh S, Mauro C, Marelli-Berg FM. CD31 exhibits multiple roles in regulating T lymphocyte trafficking in vivo. J Immunol 2012; 189: 4104-11.
20. Muller WA The role of PECAM-1 (CD31) in leukocyte emigration: studies in vitro and in vivo. J Leukoc Biol 1995; 57: 523-8.
21. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70: 6171-80.
22. Kandalaft LE, Motz GT, Duraiswamy J, Coukos G. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev 2011; 30: 141-51.
23. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kture A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008; 105: 3005-10.
24. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 2008; 105: 20410-5.
25. Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGFR pathway blockade inhibits tumorinduced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013; 73: 539-49.
26. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-68.
27. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013; 73: 2943-8.
28. Terme M, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J. Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol 2012; 2012: 492920.
29. Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008; 57: 1115-24.
30. Weyand CM, Goronzy JJ. Giant cell arteritis as an antigen-driven disease. Rheum Dis Clin North Am 1995; 21: 1027-39.
31. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-64.
32. O'Day SJ, Maio M, Chiarion-Sileni V, Gajweski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter singlearm phase II study. Ann Oncol 2010; 21: 1712-7.
33. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
34. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
35. Heitz F, Harter P, Barinoff J, Beutel B, Kannisto P, Grabowski JP, et al. Bevacizumab in the treatment of ovarian cancer. Adv Ther 2012; 29: 723-35.
36. Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011; 30: 83-95.